Publications by authors named "D Friel"

Introduction: Although cycling provides both individual and societal benefits, the mode share in Germany remains at a relatively low level. One reason described in literature is the lack of perceived safety due to the cycling infrastructure, especially at junctions. The study addresses the influence of junction design on cyclists' perceived safety.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the safety and immune response of a new RSV vaccine (ChAd155-RSV) in infants aged 6-7 months, comparing different doses and an active comparator.* -
  • The trial involved 201 infants, with results indicating that the vaccine had a safety profile comparable to existing childhood vaccines, and did not lead to adverse respiratory effects associated with RSV infections.* -
  • Higher doses of the ChAd155-RSV vaccine produced stronger immune responses, with increased antibody levels observed after vaccination, especially following the second dose.*
View Article and Find Full Text PDF

Traditional methods based on the assumption that the treatment distribution is a pure shift of the control distribution may not always hold. The possibility that an individual from the treatment group may not respond to the treatment motivates the use of a mixture distribution for the treatment group. This paper considers two test procedures based on the Wilcoxon rank-sum statistic for a group sequential design to detect the one-sided mixture alternative.

View Article and Find Full Text PDF

Introduction: The haemagglutination inhibition assay (HAI) and the virus microneutralisation assay (MN) are long-established methods for quantifying antibodies against influenza viruses. Despite their widespread use, both assays require standardisation to improve inter-laboratory agreement in testing. The FLUCOP consortium aims to develop a toolbox of standardised serology assays for seasonal influenza.

View Article and Find Full Text PDF

Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibody responses against the 3rd and 5th wave A(H7N9) viruses using the 1st wave vaccine sera from 4 vaccine groups: 1.

View Article and Find Full Text PDF